Intimation regarding Capacity addition under Regulation 30 (Read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories' board has approved a capacity expansion at its existing Dehradun plant focused on ointment manufacturing. The company plans to add 360,000 kgs of capacity, which will take the plant's total ointment manufacturing capacity from 180,000 kgs to 540,000 kgs. The current plant is running at approximately 80% utilisation, indicating room for demand-driven growth. The expansion involves an investment of around ₹30 crores to be funded through bank overdraft and internal accruals, with completion targeted within six months. The rationale cited is meeting captive demand and growing sales in both domestic and international markets.
This is a positive growth signal showing the company is investing to capture rising demand, though the debt component (bank OD) in funding means some leverage will be added. Successful execution within 6 months could support future revenue growth, but investors should track capacity utilisation post-expansion to judge whether the new capacity gets filled.